| Autor: |
Mahmoudian A; Department of Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden; Department of Movement Sciences and Health, University of West Florida, FL, USA. Electronic address: armaghan.mahmoudian@gmail.com., King LK; Department of Medicine, University of Toronto, Toronto, ON, Canada., Liew JW; Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Wang Q; Department of General Practice, Erasmus MC University Medical Center Rotterdam, the Netherlands., Appleton CT; Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada; Department of Medicine, University of Western Ontario, London, ON, Canada; Western Bone and Joint Institute, London, ON, Canada., Englund M; Department of Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden., Haugen IK; Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Lohmander LS; Department of Clinical Sciences Lund, Orthopedics, Lund University, Lund, Sweden., Runhaar J; Department of General Practice, Erasmus MC University Medical Center Rotterdam, the Netherlands., Turkiewicz A; Department of Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden., Neogi T; Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA., Hawker GA; Department of Medicine, University of Toronto, Toronto, ON, Canada. |
| Abstrakt: |
Competing Interests: Declaration of Competing Interest LKL reports support from the Canadian Institutes of Health Research Doctoral Award, and grant funding from a Physician Services Incorporated (PSI) Resident Grant. JWL reports a Pfizer research grant completed in 2021, unrelated to this work. QW reports support from Osteoarthritis and Cartilage as an Associate Editor for statistics. CTA reports grant funding and consulting/honoraria from Abbvie, Novartis, Pfizer, and Servier. ME reports grant funding from the Swedish Research Council, ERC, ALF, Kock Foundations, Gustav V 80 Year B-day Foundation, NORDFORSK, FOREUM, Foundation for Support to People With Movement Disability in Skåne, Österlund Foundation, SUS donations, consulting from Cellcolabs AB, and a leadership role as the OARSI President-elect. IKH reports consulting fees from Abbvie, GSK, and Grünenthal, and a leadership role as the OARSI Board of Directors Secretary. LSL reports consulting/honoraria from Arthro Therapeutics AB, Sweden, and participation on a DSMB board for AstraZeneca. JR reports a leadership role on the OARSI Ethics and Governance Committee, Nominating Committee. AT reports support from Osteoarthritis and Cartilage as an Associate Editor for statistics. TN reports grant funding from NIH, grant funding and consulting/honoraria from Pfizer/Lilly, Regeneron, and Novartis, and support from Osteoarthritis and Cartilage as a Deputy Editor. All other authors report no competing interests. |
Full Text from ScienceDirect